← All trials
NCT06132828
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2023
- Primary completion
- Mar 30, 2026
- Completion date
- Jul 30, 2026
- First posted
- Nov 15, 2023
- Last posted
- Dec 13, 2023
- Enrollment
- 182
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang Doer Biologics Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Zhejiang Doer Biologics Co., Ltd.Study chair
- Huadong Medicine Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.